NovaBridge Biosciences · NASDAQ:NBP
NovaBridge Biosciences — I-Mab — Investor Presentation (October 2025)
31 slides from NovaBridge Biosciences's investor presentation, Oct 16, 2025
Slide 1: Company Presentation October 2025
Company Presentation October 2025
Slide 2: Disclaimer
Disclaimer 1. The Board of Directors of the Company approved the new company name of NovaBridge, and this is subject to the shareholders’ approval. Legal Disclaimer. This presentation has been prepared by I-Mab (the “Company”)1 solely for informational purposes. Certain of the information included h
Slide 3: A Global Biotechnology Platform Bringing Paradigm-shifting Innovations Globally
A Global Biotechnology Platform Bringing Paradigm-shifting Innovations Globally 01 Company Overview
Slide 4: Emerging Biopharma Ecosystems Spearheaded by China Rise as Global Innovation Powerhouse
Emerging Biopharma Ecosystems Spearheaded by China Rise as Global Innovation Powerhouse Source: PharmaCube Clinical Trials Registration for Innovative Drugs China Biopharma Out-licensing Transactions China out-licensing deals account for ~60% of global licensing deal value in 1Q25
Slide 5: NovaBridge Marks Our Evolution into the Next Stage
NovaBridge1 Marks Our Evolution into the Next Stage 38-98-139 50-169-225 36-139-196 63-151-49 124-188-39 109-203-93 2020-2023 2023-2024 2025 onwards Immuno-oncology Autoimmune disorders 11 assets CD47 mAb / CD73 mAb / αGM-CSF Fast-to-market China strategy Fast-to-PoC (proof of concept) global strate
Slide 6: First and only listed hub-and-spoke platform bridging Asian innovations
We are the FIRST and ONLY listed hub-and-spoke platform specializing in bridging Asian innovations to the global markets Business Development Capability (BD-in and BD-out) Clinical Development Capability Existing Partners Co-co collaboration Acquisitions NewCo Licensing in/out NovaBridge1 is a Hub-a
Slide 7: Our Platform-based Business Model
Our Platform-based Business Model Emerging innovation for asset sourcing Attractive exit/spin-off Deeply rooted in emerging innovation ecosystem for long-time, with incomparable understanding of team capabilities and quality of assets from local innovators Strong exit through acquisition or robust o
Slide 8: Core Capabilities for the Success of Novel Business Model
BD-out Long standing presence in US with strong capability to provide bespoke solutions for biotech/MNCs BD-in Unparalleled healthcare ecosystem access powered by CBC Group Clinical development / translational development capabilities Unique strategies for accelerated asset development Cross-functio
Slide 9: We are Uniquely Positioned with Competitive Advantages
We are Uniquely Positioned with Competitive Advantages Strength Constraint Asset sourcing MNC Pharmas Clinical de-risking Scientific Translation Deep know-how in priority TAs Deep know-how in priority TAs US biotechs Relatively established local BD network Distant from Asian innovation sources Lack
Slide 10: Focus on the Most Significant Value Creation Step along the Innovation Value Chain
We Focus on the Most Significant Value Creation Step along the Biopharma Innovation Value Chain Discovery Pre-clinical development Clinical PoC Late phase development Registration Commerciali- zation Extended value creation step of I-Mab model Core value creation step of I-Mab model Not our focus: I
Slide 11: Our New Management Framework
Our New Management Framework Years of Industry Experience We assembled a seasoned management team composed of industry veterans with extensive regional and functional expertise Sean Fu PhD, MBA Chief Executive Officer Fu Wei Director and Executive Chairman of our Board 11 24 Claire Xu MD, PhD Senior
Slide 12: A New Wave of Growth with Highly Differentiated Assets: Pipeline Overview
A New Wave of Growth with Highly Differentiated Assets 02 Pipeline Overview
Slide 13: Givastomig
BIOPHARMA 2.1 Givastomig
Slide 14: Givastomig: A Potential Best-in-class CLDN18.2 Therapeutic
Givastomig: A Potential Best-in-class CLDN18.2 Therapeutic Unique Molecular Design to Balance Anti-Tumor Efficacy and Safety Notes: scFv = single chain Fragment-variable region; TME = tumor microenvironment; 1 L = first line; CLDN18.2 = Claudin 18.2; MHC = major histocompatibility complex; mAb = mon
Slide 15: Givastomig: Favorable Safety Profile in Combo Setting
Givastomig: Favorable Safety Profile in Combo Setting Underpins the 1st Line Potential and Broad Therapeutic Window 1. Janjigian 2021; The Lancet, Volume 398, Issue 10294, 27 - 40 2. Shitara et al. 2023; The Lancet, Volume 401, Issue 10389, 1655 - 1668 Givastomig in Combination Immuno-chemotherapy v
Slide 16: Givastomig: Superior Efficacy Improving the Current Standard of Care
Givastomig: Superior Efficacy Highlights the Significant Clinical Value by Improving the Current Standard of Care Nivolumab + mFOLFOX6 (CHECKMATE-6491, n=782) 47% Zolbetuximab + mFOLFOX6 (SPOTLIGHT2, n=279) 40% Givastomig + nivolumab + mFOLFOX6 (All doses, escalation combo, n=17) 71% ORR (%) compari
Slide 17: Givastomig: Clinical Development Plan
Givastomig: Clinical Development Plan Overall Clinical Development Plan Notes: mNSCLC = metastatic non-small cell lung cancer; Ab = antibody; mAb = monoclonal antibody, 1L = first line; IIT = investigator-initiated trials; nivo = nivolumab; CLDN18.2 Low = CLDN18.2 <75%; PD-L1 Low = CPS<1; CPI = chec
Slide 18: Givastomig: Significant Market Opportunity in Gastric Cancers and Beyond
Givastomig: Significant Market Opportunity in Gastric Cancers and Beyond Significant Market Opportunity in Gastric Cancers and Beyond 1. Markets include U.S., five E.U. countries, and Japan in 2025 based on Frost & Sullivan; 2. HER2-negative status of ~78-80% based on Frost & Sullivan; 3. CLDN18.2 p
Slide 19: VIS-101
BIOPHARMA 2.2 VIS-101
Slide 20: VIS-101: Significant Unmet Needs Remain in nAMD and DME Treatments
VIS-101: Significant Unmet Needs Remain in nAMD and DME Treatments Source: Frost & Sullivan nAMD and DME as major ophthalmology diseases and unmet needs Disease Overview Global Patient population1 Neovascular age-related macular degeneration (nAMD) One of the most common causes of significant visual
Slide 21: VIS-101: Next generation SOC with Longer Durability
VIS-101: Next generation SOC with Longer Durability, Less Priming Dose and Efficacy on Pre-treated Patients Strong Growth of Anti-VEGF-A Ophthalmology Drug Market Global revenue for anti-VEGF ophthalmology drugs is projected to grow to >$20B by 2030. VabysmoTM (faricimab) is the first VEGF/ANG-2 bis
Slide 22: VIS-101: China Randomized Phase Interim Analysis Shows BIC Potential
VIS-101: China Randomized Phase 2 Interim Analysis Shows BIC Potential In an ongoing Phase 2a study, 24 nAMD patients previously treated and treatment-naïve received 3 doses of 6mg of intravitreal injection of VIS-101 at Day 0, Week 4, and Week 8. Interim analysis showed a rapid and sustained effect
Slide 23: VIS-101: Speed-to-Market as 2nd in Class & BIC Potential
VIS-101: Speed-to-Market as 2nd in Class & BIC Potential Source: Frost & Sullivan Clinical Plan of VIS-101 2025Q3: Phase II ongoing 2026-2027Q4: Phase III head-to-head comparison to Vabysmo 2028-2029/30: Randomized Phase 3 trial readouts BLA filing nAMD Tier 1 – Marketed Faricimab (Vabysmo) Tier 2 –
Slide 24: The Ophth NewCo Led by an Exceptional Leadership Team
The Ophth NewCo Led by an Exceptional and Experienced Leadership Team Transaction Structure Visara, Inc. (NewCo) NovaBridge AffaMed ESOP 65% 30% 5% NewCo Leadership NovaBridge to contribute cash in exchange for 65% of the equity interest in Visara AffaMed to contribute its rights and interests in VI
Slide 25: Other Products
I-MA3 BIOPHARMA 2.3 Other Products
Slide 26: Ragistomig: Novel Bispecific PD-L1 x 4-1BB
Ragistomig: Novel Bispecific PD-L1 x 4-1BB with Differentiated Molecular Design and Compelling Phase 1 Clinical Data Ragistomig: A novel bispecific integrates PD-L1 as a tumor engager and 4-1BB as a conditional T cell activator Compelling Clinical Data in Phase 1, Including Significant Checkpoint In
Slide 27: Uliledlimab: A Potential Best-in-class CD73 Therapeutic
Uliledlimab: A Potential Best-in-class CD73 Therapeutic Uliledlimab: A Potential Best-in-class CD73 Therapeutic Uliledlimab + Toripalimab Data Support Patient Selection Based on CD73 Expression and Show Manageable Toxicity Anti-CD73 CD73 Biology: CD73 is the rate-limiting enzyme and a promising targ
Slide 28: Accelerating Value Creation with Shareholder Expertise and Ecosystem
Accelerating Value Creation with Shareholder Expertise and Ecosystem 03 Strategic Advantage
Slide 29: CBC is a Steadfast Investor-Operator Differentiating from Peers
CBC is a Steadfast Investor-Operator Differentiating from Peers Asia’s largest and most impactful healthcare-dedicated asset manager Investor-Operator approach Build deep expertise in value-creation levers and hands-on portfolio management, securing significantly greater exposures to top-tier assets
Slide 30: Highly Experienced World-Class Team to Support Global Strategy
Highly Experienced World-Class Team to Support Global Strategy Regional Coverage Leads Sean LU Senior Managing Director Greater China Billy CHO Senior Managing Director Korea Vijay KARWAL Managing Director SEA Global Investment Team Managing Directors Directors / Vice Presidents Neo ZHANG Managing D
Slide 31: Systematic Value Creation Driven by Vast and Dynamic Healthcare Ecosystem
Systematic Value Creation Driven by Vast and Dynamic Healthcare Ecosystem Ophthalmology Assets Small Molecule Oncology Assets Protein Conjugates & Novel ADCs Small Molecule Oncology Assets Transformative Drugs & Vaccines Neurology & Allergy Assets NeuroGen Pharma And more … Gastrointestinal Therapeu